Wall Street consensus for Bristol Myers Squibb’s fourth quarter ended December 2025 calls for top-line growth of approximately 3% year-over-year, driven by resilient oncology franchise momentum. Analysts forecast revenue near $12.6 billion, reflecting strong uptake of Opdivo and continued expansion of newly launched indications. On the bottom line, adjusted earnings per share are expected to reach $1.67, up from $1.52 in the prior-year period, reflecting operational leverage and disciplined cost control across R&D and SG&A functions. Key drivers include a projected 10% sequential increase in immuno-oncology sales and a 5% decline in legacy small-molecule products, where generic competition has intensified.

Recent 13F filings reveal that Capital Management Corp VA increased its stake in Bristol Myers Squibb by 9.6% during the third quarter, raising its holding to 111,670 shares valued at just over $5 million. Meanwhile, Norges Bank initiated a new position worth $1.55 billion, and Charles Schwab Investment Management added more than 10 million shares, lifting its total stake to over 70 million shares. In aggregate, institutional ownership stands at more than 76%, underscoring deep conviction among large investors in BMY’s pipeline prospects and dividend stability. Notably, Arrowstreet Capital and Man Group more than quadrupled and nearly quadrupled their positions, respectively, signaling a strong vote of confidence in the company’s medium-term growth trajectory.

Bristol Myers Squibb recently announced a quarterly dividend hike to $0.63 per share, representing an annualized payout of $2.52 and a yield near 4.6%. The new dividend, payable in early February to holders of record as of January 2, reflects the company’s commitment to shareholder returns, with a payout ratio around 85%. On the street, seven analysts maintain a Buy rating, twelve recommend Hold and one issues a Sell, implying a consensus ‘Hold.’ The average target suggests mid-single-digit upside to current consensus valuation, supported by a P/E ratio near 19 and a P/E/G ratio below 0.2, which together point to modest earnings growth expectations relative to industry peers.